About ESMO ESMO is the European Society for Medical Oncology. Representing more than 35,000 oncology professionals in 172 countries, ESMO is a reference for oncology education and information.

Today we highlight research findings reported at ESMO 2024, the annual meeting of the European Society of Medical Oncology.

Bowers added that to increase access to the latest drugs, the "cancer system" must be organized in such a way as to ...

Before the annual congress of the European Society for Medical Oncology began in Barcelona, clinicians held a press ...

Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine ...

The European Society for Medical Oncology (ESMO) is calling on all actors of the oncology community to commit to improving the well-being of the cancer workforce and join in 11 actions outlined in a ...

A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentation has concluded. About BioAtla®, Inc.

RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology for cancer profiling, is pleased to announce two ...

Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) orelabrutinib were presented at the European Society for Medical Oncology (ESMO) Congress 2024. A Prospective Study of Orelabrutinib plus ...

SOLARIS (Alliance A021703), a multicenter, double-blind, randomized Phase III clinical trial led by Dana-Farber Cancer ...